Evidence-based review of therapies at the menopause

International Journal of Evidence-Based Healthcare

Volumn 7, Issue 2, 2009, Pages 112-123

  MacLennan, Alastair H ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Complementary therapy; Evidence based review; Hormone replacement therapy; Menopause

Indexed keywords

EID: 77952742259     PISSN: 17441595     EISSN: 17441609     Source Type: Journal    
DOI: 10.1111/j.1744-1609.2009.00133.x     Document Type: Article

References (69)

1. National Health and Medical Research Council. A Guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines. Canberra: NHMRC, 1999. Accessed May 2007. Available from: http://www.nhmrc.gov.au/publications/synopses/cp30syn.htn
2. Col NF, Guthrie JR, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause 2009; 16: epub. DOI: 10.1097/gme.0b013e31818d414e.
3. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 2006; 184: 27-31.
4. Maclennan AH, Gill TK, Broadbent JL, Taylor AW. Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 2009; 12: 122-30.
5. Parente RC, Faerstein E, Celeste RK, Werneck GL. The relationship between smoking and age at the menopause: a systematic review. Maturitas 2008; 61: 287-98.
6. Moriyama KC, Oneda B, Bernardo FR et al. A randomized, placebo-controlled trial of the effects of physical exercises and estrogen therapy on health-related quality of life in menopausal women. Menopause 2008; 15: 613-18.
7. Sowers M, Zheng J, Tomey K et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007; 92: 895-901.
8. Norman RJ, Flight IHK, Rees MCP. Oestrogen and Progestogen Hormone Replacement Therapy for Perimenopausal and Postmenopausal Women: Weight and Body Fat Distribution (Cochrane Review). In the Cochrane Library. Oxford: Update software, 2001.
9. Torgerson DJ, Campbell MK, Thomas RE, Reid DM. Alcohol consumption may influence onset of the menopause. BMJ 1997; 315: 188.
10. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003; 237: 474-82.
11. The Board of the Trustees of the North American Menopause Society. The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006; 13: 862-77.
12. Avis NE, Ory MG, Mathews KA, Shocken M, Bromberger J, Colvin A. Health-related quality of life in a multiethnic sample of middle-aged women. Med Care 2003; 41: 12262-76.
13. Elavsky S, McAuley E. Physical activity, symptoms, esteem, and life satisfaction during menopause. Maturitas 2005; 52: 374-85.
14. Elavsky S. Physical activity, menopause, and quality of life: the role of affect and self-worth across time. Menopause 2009; 16: 265-71.
15. Nedrow A, Miller J, Walker M, Nygren P, Huffman LH, Nelson HD. Complementary and alternative therapies for the management of menopause-related symptoms. Arch Intern Med 2006; 166: 1453-65.
16. Singh S, Ernst E. Trick or Treatment? Alternative Medicine on Trial. London: Bantam Press, 2008.
17. Hurley D. Natural Causes. Death, Lies and Politics in America's Vitamin and Supplement Industry. New York: Broadway, 2006.
18. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; CD002978. DOI: 10.1002/14651858.CD002978.pub2.
19. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Erlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy hormone therapy, or placebo:a randonized trial. Ann Intern Med 2006; 145: 869-79.
20. Mahady GB, Dog TL, Barrett ML et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008; 15: 628-38.
21. Huntley L, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003; 10: 465-76.
22. Lee MS, Shin BC, Ernst E. Acupuncture for treating menopause hot flushes: a systematic review. Climacteric 2009; 12: 16-25.
23. Chattha R, Raghuram N, Venkatram P, Hongasandra ME. Treating the climacteric symptoms in Indian women with an integrated approach to yoga therapy: a randomized control study. Menopause 2008; 15: 862-79.
24. Boothby LA, Doering PL, Kipersztok S. Bioidenticakl hormone therapy: a review. Menopause 2004; 11: 356-67.
25. MacLennan AH. The 'Bioidentical/bioequivalent' hormone scam. Climacteric 2006; 9: 1-3.
26. Maclennan AH. The four harms of harmless therapies. Climacteric 1999; 2: 73-4.
27. Nelson HD, Vesco KK, Haney E et al. Non-hormonal therapies for menopausal hot flashes: systematic review and metaanalysis. JAMA 2006; 295: 2057-71.
28. Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal symptoms. Treat Endocrinol 2006; 5: 83-7.
29. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlaflaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008; 24: 1877-90.
30. Boyer P, Montgomery S, Lepola U et al. Efficacy, safety and tolerability of fixed-dose desvenlaflaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008; 23: 243-53.
31. Reddy SY, Warner H, Guttuso T et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108: 41-8.
32. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flushes: a randomised controlled trial. Menopause 2008; 15: 310-18.
33. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
34. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701-12.
35. Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335: 234-44.
36. Welton AJ, Vickers MR, Kim J et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008; 337: a1190. DOI: 10.1136/bmj.a1190 (published 22/8/08).
37. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006; 15: 35-44.
38. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003; CD001500. DOI: 10.1002/14651858. CD001500.
39. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005; 83: 558-66.
40. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-77.
41. Salpeter SR, Walsh ME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone therapy in younger and older women. J Gen Internal Med 2004; 19: 791-804.
42. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen intern Med 2006; 21: 363-6.
43. MacLennan AH, Taylor AW, Wilson DH. Hormone therapy use after the Women's Health Initiative. Climacteric 2004; 7: 138-42.
44. Sturdee DW, MacLennan AH. Should epidemiology, the media and quangos determine clinical practice? Climacteric 2004; 7: 1-2.
45. MacLennan AH, Sturdee DW. Long-term trials of HRT for cardioprotection - is this as good as it gets? Climacteric 2007; 10: 1-4.
46. Manson JE, Allison MA, Rossouw JE et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356: 2591-602.
47. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-59.
48. Norman RJ, MacLennan AH. Current status of hormone therapy and breast cancer. Hum Reprod Update 2005; 11: 541-3.
49. Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of breast cancer. A meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update 2005; 11: 561-73.
50. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with post menopausal hormonal treatment. Hum Reprod Update 2005; 11: 545-60.
51. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
52. Anderson GL, Chlebowski RT, Rossouw JE et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial plus progestin. Maturitas 2006; 55: 103-5.
53. Chen WY, Manson JA, Hankinson SE et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006; 166: 1027-32.
54. La Vecchia C. Estrogen-progestogen replacement therapy and ovarian cancer: an update. Eur J Cancer Prev 2006; 15: 490-92.
55. Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-10.
56. Cushman M, Kuller LH, Prentice R et al., for the Women's Health Investigators Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-80.
57. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-2.
58. Sturdee DW, MacLennan AH. Prevention of osteoporosis is still a valid aim for hormone therapy. Climacteric 2005; 8: 97-8.
59. MacLennan AH, Henderson VW, Paine BJ et al. Hormone therapy, timing of initiation, and cognition in women older than 60 years: the REMEMBER pilot study. Menopause 2006; 13: 28-36.
60. Schumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. JAMA 2004; 291: 2947-58.
61. Resnick SM, Espland MA, Jaramillo SA et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 2009; 72: 135-42.
62. Zandi PP, Carlson MC, Plassman BL et al., for the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer Disease in older women. J Am Med Assoc 2002; 288: 2123-9.
63. Clark JH. A critique of Women's Health Initiative Studies. 2002-2006. Nucl Recept Signal 2006; 4 (e023): 1-10.
64. MacLennan AH. HRT: a reappraisal of the risks and benefits. Med J Aust 2007; 186: 643-6.
65. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005; 51: 21-8.
66. Kennemans P, Bundred NJ, Foidart J et al., for the Liberate Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, noninferiority trial. Lancet Oncol. 2009; 10: 135-46.
67. Cummings SR, Ettinger B, Delmas PD et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697-708.
68. The Board of the Trustees of the North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women. March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168-82.
69. Board of the International Menopause Society. International Menopause Society updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181-94.